// App-Quantinova.ai

e12550 : Phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients with GR-positive (GR+) triple-negative breast cancer (TNBC).

Researchers

Presenter

  • Sharon Wilks

Principal Investigators

  • Manuel R. Modiano

  • Alexander I. Spira

  • Carlos Becerra

  • Hyo S. Han

  • Fadi S. Braiteh

  • Elisavet Paplomata

  • Timothy J. Pluard

  • Donald A. Richards

  • Joyce O'Shaughnessy

  • Jackie Walling

  • Robert S. Fishman

  • Gabrielle Baker

  • Suzanne D. Conzen

  • Rita Nanda

Medical Centers

  • Texas Oncology San Antonio, San Antonio, TX

  • ACRC/Arizona Clinical Research Center and Arizona Oncology, Tucson, AZ

  • Virginia Cancer Specialists Research Institute, and Oncology Research, Fairfax, VA

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • Moffitt Cancer Center, Tampa, FL

  • The US Oncology Network/McKesson Specialty Health, The Woodlands, TX

  • Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA

  • St Luke's Cancer Institute, Kansas City, MO

  • Tyler Cancer Center, US Oncology Research, McKesson Specialty Health, Houston, TX

  • Baylor University Medical Center, Texas Oncology, Dallas, TX

  • JW Consulting, Hillsborough, CA

  • Corcept Therapeutics, Menlo Park, CA

  • The University of Chicago Medical Center, Chicago, IL

  • Section of Hematology/Oncology, University of Chicago, Chicago, IL

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • United States

Companies

  • JWC Consultants, LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Solid malignancies

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Glucocorticoid

  • Mifepristone

  • Eribulin

Outcome

  • Unknown

Study Design

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT02014337

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved